Streetwise Reports' Article Archives — June 2019 back to current month (21)
The company shared findings from its lead clinical program, in Alzheimer's disease.
The firm believes adequate therapeutic safety and efficacy data exist to support regulatory approval.
The pharmaceutical stock enjoyed a large boost, thanks largely to FDA approval of its supplemental new drug application for DOPTELET for treatment of chronic immune thrombocytopenia.
The deal terms and the partner's attractive attributes are discussed in an H.C. Wainwright & Co. report.
The reasons why this biopharma makes a compelling investment are outlined in a ROTH Capital Partners report.
The procedure resulted in two types of cannabinoids: water soluble and oil based.
The expert brings to the board a deep knowledge of neurodegeneration.
The data and how the asset stacks up to others were covered in a ROTH Capital Partners report.
The highlights of the results were presented in an H.C. Wainwright & Co. report.
The company received approval to proceed with the next and final dose level.
Cannabis Producer Achieves Commercial Sale Milestone (06/19/2019)
The transaction marks the start of a revenue stream for the company.
The new partner has expertise in online marketing and e-commerce.
The product's improvements and the company's commercialization approach were summarized in a Ladenburg Thalmann report.
A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report.
These new customers' patient accounts are already being imported into the company's platform.
The focus will be the Canadian company's lead monoclonal antibody candidate.
An explanation of the categorization and its implications are provided in a Paradigm Capital report.
The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report.
The reasons for the Buy rating on the U.K. firm are delineated in a ROTH Capital Partners report.
The company's recent deal, progress on its cannabis beverages and its product ideas for the future were discussed.
The offering should facilitate a more individualized treatment plan for patients.
|"From a stock perspective, 2019 was a clear breakout year for DRRX."|